Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 4
2007 6
2008 1
2009 2
2011 1
2012 1
2013 3
2014 3
2015 6
2016 2
2017 4
2018 8
2019 1
2020 2
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
Wang GP, Schnell GL, Kort JJ, Sidhu GS, Schuster L, Tripathi RL, Larsen L, Michael LC, Bergquist K, Magee A, Patel CB, Whitlock JA, Tamashiro R, Peter JA, Fried MW, Nelson DR. Wang GP, et al. Among authors: tripathi rl. J Hepatol. 2021 Oct;75(4):820-828. doi: 10.1016/j.jhep.2021.04.057. Epub 2021 May 21. J Hepatol. 2021. PMID: 34023351 Free article.
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.
Shebley M, Wang S, Ali I, Krishnan P, Tripathi R, Reardon JM, Cafardi J, Rahav G, Caraco Y, Slim J, Al Akhrass F, Yu M, Hu Y, Ferreira RA, Alami NN. Shebley M, et al. Among authors: tripathi r. Pharmacol Res Perspect. 2023 Feb;11(1):e01036. doi: 10.1002/prp2.1036. Pharmacol Res Perspect. 2023. PMID: 36537346 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.
Jonas MM, Rhee S, Kelly DA, Del Valle-Segarra A, Feiterna-Sperling C, Gilmour S, Gonzalez-Peralta RP, Hierro L, Leung DH, Ling SC, Lobzin Y, Lobritto S, Mizuochi T, Narkewicz MR, Sabharwal V, Wen J, Kei Lon H, Marcinak J, Topp A, Tripathi R, Sokal E. Jonas MM, et al. Among authors: tripathi r. Hepatology. 2021 Jul;74(1):19-27. doi: 10.1002/hep.31841. Hepatology. 2021. PMID: 33811356 Free PMC article. Clinical Trial.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Pessoa MG, Ramalho-Madruga JV, Alves K, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Correa MC, Ferraz ML, Ferreira PRA, Álvares-da-Silva MR, Coelho HS, Affonso-de-Araújo ES, Furtado J, Parana R, Silva G, Lari SA, Liu L, Tripathi R, Pilot-Matias T, Cohen DE, Shulman NS, Martinelli A. Pessoa MG, et al. Among authors: tripathi r. Ann Hepatol. 2018 Oct 16;17(6):959-968. doi: 10.5604/01.3001.0012.7196. Ann Hepatol. 2018. PMID: 30600291 Free article. Clinical Trial.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L Jr, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Schnell G, et al. Among authors: tripathi r. J Med Virol. 2018 Jan;90(1):109-119. doi: 10.1002/jmv.24923. Epub 2017 Sep 22. J Med Virol. 2018. PMID: 28842997 Free PMC article. Clinical Trial.
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins C, Pilot-Matias T. Krishnan P, et al. Among authors: tripathi r. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02217-17. doi: 10.1128/AAC.02217-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29180522 Free PMC article. Clinical Trial.
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. Ng TI, et al. Among authors: tripathi r. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01620-17. doi: 10.1128/AAC.01620-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29084747 Free PMC article.
46 results